2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

2:30PM-4:00PM: Abstract Number: 1847

Screening Youth with Lupus for Depression and Anxiety in Pediatric Rheumatology Clinics

4M084 ACR Abstract: Pediatric Rheum–Clinical I: Outcomes & Comorbidities (1846–1851)

2:30PM-4:00PM: Abstract Number: 1888

SLE Among the Leading Causes of Years of Potential Life Lost in Young Women: Population-Based Study, 2000-2015

4M094 ACR/ARHP Abstract: Health Services Research I: Focus on Big Data (1887–1892)

2:30PM-4:00PM: Abstract Number: 1854

SLE Flares during and after Pregnancy Are Mild and Occur at Similar Rates

4M087 ACR Abstract: Reproductive Issues in Rheumatic Disorders (1852–1857)

2:30PM-4:00PM: Abstract Number: 1834

Sleep Apnea and Fibromyalgia: Data from the Cleveland Clinic Fibromyalgia Registry

4M082 ACR Abstract: Fibromyalgia & Other Clinical Pain Syndromes (1834–1839)

2:30PM-4:00PM: Abstract Number: 1877

Specific Pneumoproteins Predict Progression of Interstitial Lung Disease in Systemic Sclerosis Patients Undergoing Treatment with Immunosuppression

4M090 ACR Abstract: Systemic Sclerosis & Rel D/O–Clinical II: Clinical Trials II (1875–1880)

2:30PM-4:00PM: Abstract Number: 1869

Sustained Improvements in Signs and Symptoms of Active Ankylosing Spondylitis and Reassuring Safety with Secukinumab 300mg: 3-Year Results from a Phase 3 Study

4M089 ACR Abstract: Spondyloarthritis Incl PsA–Clinical III: Treatment of Axial SpA (1864–1869)

2:30PM-4:00PM: Abstract Number: 1879

The Effects of Riociguat on Raynaud’s Phenomenon and Digital Ulcers in Patients with Diffuse Systemic Sclerosis: Results from the Phase IIb RISE-SSc Study

4M090 ACR Abstract: Systemic Sclerosis & Rel D/O–Clinical II: Clinical Trials II (1875–1880)

2:30PM-4:00PM: Abstract Number: 1859

The Prognostic Value of Autoantibody Isotypes for Predicting Therapeutic Responses to Methotrexate in Patients with Rheumatoid Arthritis

4M086 ACR Abstract: RA–DX, Manifestations, & Outcomes II: DX & Prognosis I (1858–1863)

2:30PM-4:00PM: Abstract Number: 1833

The Vδ2 Subset of Γδt-Cells Are Present at Healthy Human Enthesis and Have Transcriptional and Functional Characteristics Consistent with a Capacity for IL- 17A Production in Response to IL-23

4M088 ACR Abstract: Spondyloarthritis Incl PsA–Basic Science (1828–1833)

2:30PM-4:00PM: Abstract Number: 1837

Validity of the Cognitive Index of the Symptom Severity Scale (SSS-Cog) in Assessing Cognitive Impairment in Fibromyalgia Patients

4M082 ACR Abstract: Fibromyalgia & Other Clinical Pain Syndromes (1834–1839)

4:30PM-6:00PM: Abstract Number: 1938

A Phase IIb Dose-Ranging Study of Anti-GM-CSF with Methotrexate Treatment in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Methotrexate

4M106 ACR Abstract: RA–Treatments III: New Compounds & Biosimilars (1935–1940)

4:30PM-6:00PM: Abstract Number: 1936

A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis

4M106 ACR Abstract: RA–Treatments III: New Compounds & Biosimilars (1935–1940)

4:30PM-6:00PM: Abstract Number: 1906

Abdominal Obesity and Risk of Developing Rheumatoid Arthritis in Women

4M101 ACR Abstract: Epidemiology & Pub Health II: RA Risk: Education, Obesity, Smoking, or Biomarkers? (1905–1910)

4:30PM-6:00PM: Abstract Number: 1931

Abundance of Plasma Microbial Small RNAs Are Predictive of Improvement in Disease Activity after DMARD Initiation for Rheumatoid Arthritis

4M105 ACR Abstract: RA–DX, Manifestations, & Outcomes III: Diagnosis & Prognosis II (1929–1934)

4:30PM-6:00PM: Abstract Number: 1941

Altered Cognitive Function in Systemic Lupus Erythematosus and Associations with Inflammation and Functional Brain Changes

4M107 ACR Abstract: SLE–Clinical II: Renal & Neuropsychiatric Disease in SLE (1941–1945)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].